ArticleProceedings of the National Academy of Sciences of the United States of America2000
Vigilin binding selectively inhibits cleavage of the vitellogenin mRNA 3'-untranslated region by the mRNA endonuclease polysomal ribonuclease 1.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 85 citations in OpenAlex.
- The DNMT1-PAS1-PH20 axis drives breast cancer growth and metastasis.Signal transduction and targeted therapy · 2022Article
- Autism-Associated Vigilin Depletion Impairs DNA Damage Repair.Molecular and cellular biology · 2021Article
- An RNA-centric dissection of host complexes controlling flavivirus infection.Nature microbiology · 2019Article
- The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation.Nature communications · 2016Article
- FAM46 proteins are novel eukaryotic non-canonical poly(A) polymerases.Nucleic acids research · 2016Article
- Modeling the endocrine control of vitellogenin production in female rainbow trout.Mathematical biosciences and engineering : MBE · 2014Article
- Characterization of the distal polyadenylation site of the ß-adducin (Add2) pre-mRNA.PloS one · 2013Article
- Vigilin interacts with signal peptide peptidase.Proteome science · 2012Article
- Posttranscriptional suppression of proto-oncogene c-fms expression by vigilin in breast cancer.Molecular and cellular biology · 2011Article
- Vgl1, a multi-KH domain protein, is a novel component of the fission yeast stress granules required for cell survival under thermal stress.Nucleic acids research · 2010Article
- Novel endoribonucleases as central players in various pathways of eukaryotic RNA metabolism.RNA (New York, N.Y.) · 2010Review
- KSRP-PMR1-exosome association determines parathyroid hormone mRNA levels and stability in transfected cells.BMC cell biology · 2009Article
- Interactions between estrogen- and Ah-receptor signalling pathways in primary culture of salmon hepatocytes exposed to nonylphenol and 3,3',4,4'-tetrachlorobiphenyl (congener 77).Comparative hepatology · 2007Article
- Positive and negative regulation of chicken anemia virus transcription.Journal of virology · 2005Article
- Endonuclease-mediated mRNA decay requires tyrosine phosphorylation of polysomal ribonuclease 1 (PMR1) for the targeting and degradation of polyribosome-bound substrate mRNA.The Journal of biological chemistry · 2004Article
- The aryl hydrocarbon receptor-mediated disruption of vitellogenin synthesis in the fish liver: Cross-talk between AHR- and ERalpha-signalling pathways.Comparative hepatology · 2004Article
- Both KH and non-KH domain sequences are required for polyribosome association of Scp160p in yeast.Nucleic acids research · 2004Article
- Genetic and biochemical interactions between SCP160 and EAP1 in yeast.Nucleic acids research · 2003Article
- RNAi-mediated depletion of the 15 KH domain protein, vigilin, induces death of dividing and non-dividing human cells but does not initially inhibit protein synthesis.Nucleic acids research · 2003Article
- An endonuclease activity similar to Xenopus PMR1 catalyzes the degradation of normal and nonsense-containing human beta-globin mRNA in erythroid cells.RNA (New York, N.Y.) · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
In Xenopus, estrogen induces the stabilization of vitellogenin mRNA and the destabilization of albumin mRNA. These processes correlate with increased polysomal activity of a sequence-selective mRNA endonuclease, PMR-1, and a hnRNP K homology-domain RNA-binding protein, vigilin. Vigilin binds to a region of the vitellogenin mRNA 3'-untranslated region (3'-UTR) implicated in estrogen-mediated stabilization. The vigilin-binding site in the vitellogenin B1 mRNA 3'-UTR contains two consensus PMR-1 cleavage sites. The availability of purified PMR-1 and recombinant vigilin made it possible to test the hypothesis that RNA-binding proteins interact with cis-acting elements to stabilize target mRNAs by blocking cleavage by site-specific mRNA endonucleases. Vigilin binds to the vitellogenin mRNA 3'-UTR site with at least 30-fold higher affinity than it exhibits for the albumin mRNA segment containing the mapped PMR-1 cleavage sites. This differential binding affinity correlates with differential in vitro susceptibility of the protein-RNA complexes to cleavage by PMR-1. Whereas recombinant vigilin has no detectable protective effect on PMR-1 cleavage of albumin mRNA, it retards in vitro cleavage of the vitellogenin mRNA 3'-UTR by purified PMR-1. The PMR-1 sites in the vitellogenin mRNA 3'-UTR are functional because they are readily cleaved in vitro by purified PMR-1. These results provide direct evidence for differential susceptibility to endonuclease-mediated mRNA decay resulting from the differential affinity of a RNA-binding protein for cis-acting stability determinants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.